Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis

Toyama, Tadashi, Neuen, Brendon L., Jun, Min, Ohkuma, Toshiaki, Neal, Bruce, Jardine, Meg J., Heerspink, Hiddo L., Wong, Muh Geot +3 more·2019·Diabetes, Obesity and Metabolism
DOI 10.1111/dom.13648

Cited by (330)

Items 201–300 of 330

  1. A comprehensive risk factor analysis using association rules in people with diabetic kidney disease
    Tadashi Toyama, Miho Shimizu, Taihei Yamaguchi, Hidekazu Kurita, Tetsurou Morita, Megumi Oshima, Shinji Kitajima, Akinori Hara, Norihiko Sakai, Atsushi Hashiba et al. · 2023 · Scientific Reports
  2. Impact of Dapagliflozin Adjunctive Therapy on Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes and CKD Stage 2–5
    Kanimozhi M, Manisha Bisht, Sikha Morang, Surabhi Thapliyal, Manbir S. Bassan, Shailendra S. Handu · 2023 · Sultan Qaboos University medical journal
  3. SGLT2 inhibition, venous thrombolism, and death due to cardiac causes: a mediation Mendelian randomization study
    Lili Shi, Xiupan Wei, Jinlan Luo, Ling Tu · 2024 · Frontiers in Cardiovascular Medicine
  4. A multi-trait GWAS identifies novel genes influencing albuminuria
    Hsiao‐Mei Tsao, Tai‐Shuan Lai, Yi‐Cheng Chang, Chia‐Ni Hsiung, I‐Jung Tsai, Yu‐Hsiang Chou, Vin‐Cent Wu, Shuei‐Liong Lin, Yung‐Ming Chen · 2024 · Nephrology Dialysis Transplantation
  5. Long-term trajectory of renal dysfunction and related risk factors in patients with apparently treatment-resistant and non-resistant arterial hypertension
    Zdeněk Ramík, Jan Václavík, Tomáš Kvapil, Libor Jelínek, Eva Kociánová, Monika Kamasova, Klára Benešová, Jiří Jarkovský, Martin Drápela, Zdeněk Lys · 2024 · Blood Pressure
  6. Cardioprotection of Canagliflozin, Dapagliflozin, and Empagliflozin: Lessons from preclinical studies
    Rayla Rodrigues Soares, Larissa Freitas Viggiani, Juliano Moreira Reis Filho, Julliane Vasconcelos Joviano‐Santos · 2024 · Chemico-Biological Interactions
  7. Glucometabolic Efficacy of the Empagliflozin/Metformin Combination in People with Type 1 Diabetes and Increased Cardiovascular Risk: A Sub-Analysis of a Pilot Randomized Controlled Trial
    Miodrag Janić, Andrej Janež, Mišo Šabović, Mohamed El‐Tanani, Imran Rashid Rangraze, Manfredi Rizzo, Mojca Lunder · 2024 · Journal of Clinical Medicine
  8. Sodium-glucose co-transporter 2 inhibitors: a pleiotropic drug in humans with promising results in cats
    Aline Bomfim Vieira, Sarah M. Cavanaugh, Bianca Torres Ciambarella, Marcus Vinícius Ribeiro Machado · 2025 · Frontiers in Veterinary Science
  9. Causal impact of elevated body mass index on diabetic kidney disease: an integrated Mendelian randomization and Global Burden of Disease Study 2021 analysis
    Ye-xin Chen, Dong-sen Hu, Mao-xuan Lin, Zi-heng Gao, Han-zhang Hong, Yingjia Hu, Lingzi Yao, Gai-wen Cui, Lin Wang · 2025 · Renal Failure
  10. Impact of SGLT Inhibitors on Multiple Organ Defects in Diabetes
    Mohamed Asrih, Karim Gariani · 2019 · Current Diabetes Reviews
  11. Comprehensive efficacy of ipragliflozin on various conditioned type 2 diabetes compared with dipeptidyl peptidase-4 inhibitors and with both agents, based on a real-world multicenter trial
    Fumio Sawano, Nozomu Kamei, Mitsue Miyahara, Kyoko Kobuke, Shuhei Nakanishi, Chihiro Nagano, Hideki Nojima, Shusaku Maeda, Hiroshi Watanabe, Rui Kishimoto et al. · 2021 · Diabetology International
  12. Hypoxia-Inducible Factor-Prolyl-Hydroxylase and Sodium-Glucose Cotransporter 2 Inhibitors for Low-Risk Myelodysplastic Syndrome-Related Anemia in Patients with Chronic Kidney Disease: A Report of Three Cases
    Satoshi Yamasaki, Takahiko Horiuchi · 2023 · Hematology Reports
  13. Relationships between kidney dysfunction and left ventricular diastolic dysfunction: a hospital-based retrospective study
    Yoshiyasu Miyajima, Tadashi Toyama, Mika Mori, Yusuke Nakade, Kōichi Sato, Yuta Yamamura, Hisayuki Ogura, Shiori Nakagawa, Megumi Oshima, Taro Miyagawa et al. · 2021 · Journal of Nephrology
  14. [Retracted] Effect of Dapagliflozin on Clinical Outcome after Drug‐Eluting Stent Implantation in Elderly T2DM Patients: A Real‐World Study
    Yuan Lin, Fang Zhou, Xihu Wang, Yaju Guo, Weiguo Chen · 2023 · Computational and Mathematical Methods in Medicine · Retracted
  15. The protective effect of sodium-glucose cotransporter-2 inhibitor on left ventricular global longitudinal strain in patients with type 2 diabetes mellitus according to disease duration
    Ziying Wang, Long Huang, Leilei Han, Xiangsui Hu, Mingyi Dong, Chunquan Zhang, Liangyun Guo, Shengbo Liu, Lingmin Liao · 2025 · Scientific Reports
  16. Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed
    Alberto Martínez‐Castelao, José Luis Górriz, Beatriz Fernández‐Fernández, María José Soler, Juan F. Navarro‐González · 2025 · Journal of Clinical Medicine
  17. SGLT2 Inhibitors in Patients with Heart Failure: A Model-Based Meta-Analysis
    Na Wang, Zhen Wu, Jianwei Ren, Xin Zheng, Xiaohong Han · 2024 · Clinical Pharmacokinetics
  18. Evaluation of the hypoglycemic and hypotensive efficacy of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A model-based dose–response network meta-analysis
    Sanbao Chai, Fengqi Liu, Pei Li, Siyan Zhan, Sun Feng · 2025 · Intelligent Pharmacy
  19. Antidiabetic Drugs Consumption in France Over a Decade: An Observational Study
    David De Bandt, Johanna Mezence, Claire Rives‐Lange, Dominik Menges, Claire Carette · 2025 · Clinical Therapeutics
  20. Clinical Predictors of the Hypoglycemic Effect of Sodium–Glucose Co-transporter-2 Inhibitors in Hyperuricemic Patients: A Retrospective Descriptive Observational Study
    Toshinori Hirai, Yuya Kawagoe, Motoki Kei, Ryuichi Ogawa, Toshimasa Itoh · 2020 · Biological and Pharmaceutical Bulletin
  21. Effectiveness of triple therapy with dapagliflozin add-on to dual therapy over 52 weeks in patients with uncontrolled type 2 diabetes mellitus in a centre of high complexity, Cali-Colombia
    Vanessa Bedoya‐Joaqui, Nathalia Buitrago Gómez, Reinaldo Carvajal Ortiz, Luis Miguel Osorio-Toro, Jenny Patricia Muñoz-Lombo, Carlos Alberto Salgado Cifuentes, Mónica Andrea Morales García, Alín Abreu-Lomba · 2021 · Archives of Endocrinology and Metabolism
  22. Sodium–glucose cotransporter 2 inhibitors for the management of type 2 diabetes
    Maka Siamashvili, Stephen N. Davis · 2021 · Expert Opinion on Pharmacotherapy
  23. SGLT-2-gátló kezelés diabeteses és nem diabeteses vesebetegségben
    Gergő Attila Molnár, Eszter Sélley, István Wittmann · 2021 · Diabetologia Hungarica
  24. Changes in Cardiovascular and Renal Biomarkers Associated with SGLT2 Inhibitors Treatment in Patients with Type 2 Diabetes Mellitus
    Μelpomeni Peppa, Aspasia Manta, Ioanna Mavroeidi, Athina Asimakopoulou, Alexandros Syrigos, Constantinos Nastos, Emmanouil A. Pikoulis, Αναστάσιος Κόλλιας · 2023 · Pharmaceutics
  25. Empagliflozin, a sodium‐glucose cotransporter inhibitor enhancing mitochondrial action and cardioprotection in metabolic syndrome
    Yunhao Li, Zhanming Zhang, Zheming Zhang, Ningning Zheng, Xudong Ding · 2024 · Journal of Cellular Physiology
  26. Towards Optimal Cardiovascular Health: A Comprehensive Review of Preventive Strategies
    Philip Branigan, Y. V Duong, Ammar Abdulfattah, Jacob Sabu, Mary C. Mallappallil, Sabu John · 2024 · Cureus
  27. Acute interstitial nephritis related to SGLT-2 inhibitor
    Alon Bnaya, Eyal Itzkowitz, Jawad Atrash, Mohsen Abu‐Alfeilat, Linda Shavit · 2021 · Postgraduate Medical Journal
  28. Hypertension Treatment in Diabetes
    Hannah F. Bensimhon, Matthew Aaron Cavender · 2019 · Heart Failure Clinics
  29. Signal mining of adverse drug events related to hypovolemia caused by SGLT2 inhibitors based on FAERS database
    Huan Li, Ziwan Guan · 2025 · International Journal of Diabetes in Developing Countries
  30. SGLT2 inhibitors do not cause de novo urinary incontinence in diabetic female patients with chronic kidney disease
    Özant Helvacı, Ayşegül Karaoğlan, Burçak Cavnar Helvacı, Galip Güz, Hatîce Paşaoğlu · 2025 · International Urology and Nephrology
  31. Targeting hepatocyte-specific SLC2A8 blocks hepatic steatosis and dissociates TCA cycle flux inhibition from glutamine anaplerosis
    Joshua A. Adams, Yiming Zhang, Jiameng Sun, Andrew Tilston-Lünel, Cassandra B. Higgins, Monique R. Heitmeier, Samuel J. Ballentine, Eric Tycksen, Roland E. Dolle, Paul W. Hruz et al. · 2025 · Hepatology Communications
  32. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in the treatment of diabetic kidney disease: a meta-analysis
    Yingbo Guo, Wenfeng Gao, Shichao Li, Xiaona An, Zhongjie Liu · 2026 · Frontiers in Endocrinology
  33. Empagliflozin mitigated cisplatin induced renal endothelial dysfunction in rats via repressing oxidative, inflammatory, apoptotic and fibrotic signals
    Rasha M. Gaballah, Marwa Y. Sallam, Samar S. Elblehi, Sahar M. El‐Gowilly, Elham A. Afify · 2026 · Biomedicine & Pharmacotherapy
  34. Inhibidores de la SGLT2. ¿Cuál es el lugar en terapéutica?
    Patxi Ezkurra Loiola · 2020 · FMC - Formación Médica Continuada en Atención Primaria
  35. Long-term trajectory of estimated glomerular filtration rate in ambulatory patients with type 2 diabetes and heart failure: clinical insights and prognostic implications
    María Teresa Julián, Pau Codina, Josep Lupón, Elisabet Zamora, Alejandra Pérez-Montes de, Mar Domingo, Evelyn Santiago‐Vacas, Andrea Borrellas, María Ruiz-Cueto, Carlos González-Gallego et al. · 2025 · Cardiovascular Diabetology
  36. A Phase I Study on the Pharmacokinetics and Pharmacodynamics of DJT1116PG, a Novel Selective Inhibitor of Sodium-glucose Cotransporter Type 2, in Healthy Individuals at Steady State
    Hong Zhang, Jingrui Liu, Xiaoxue Zhu, Xiaojiao Li, Hong Chen, Min Wu, Cuiyun Li, Yanhua Ding · 2020 · Clinical Therapeutics
  37. Repercussões cardiovasculares do uso de inibidores de SGLT2 em portadores de Diabetes Mellitus tipo 2
    Thaiz Geovana Bezerra, Ana Luiza Gomes Gonçalves, Andrezza Mendes Franco, Bruna Araújo Rossi, Gabriela Aparecida Schiefler Gazzoni, Marcella Lourenço Winter, Mariana Oshiro Marques, Sophia Bark, Vinícius Sippel Cruz, Rachel Cardoso Lopes Rêgo · 2021 · Revista Eletrônica Acervo Saúde
  38. Effects of SGLT2 inhibitors on cardiovascular death and all-cause death in patients with type 2 diabetes and chronic kidney disease: an updated meta-analysis including the SCORED trial
    Limin Zhao, Ze‐Lin Zhan, Mei Qiu · 2021 · Therapeutic Advances in Endocrinology and Metabolism
  39. Sodium-Glucose Co-Transporter 2 Inhibitors Use Improves the Satisfaction With Anti-diabetic Agent Treatment: A Questionnaire-based Propensity Score-matched Study
    Fang‐Hong Shi, Jiang Yue, Yihong Jiang, Minglan Yang, Zhi‐Chun Gu, Jing Ma, Hao Li · 2022 · Frontiers in Pharmacology
  40. Current topics of possible pharmacotherapy for chronic kidney disease (CKD) and diabetes
    Hiroshi Bando, Yoshikane Kato, Sayuri Matsuzaki, Shinnichi Waka · 2020 · Pharmacy & Pharmacology International Journal
  41. Hypoglykämie unter SGLT2-Inhibition bei einem Patienten mit HFrEF ohne Diabetes mellitus
    Hendrik Schmidt, Axel Schlitt · 2022 · DMW - Deutsche Medizinische Wochenschrift
  42. Unilateral proliferative sickle retinopathy: a model for photocoagulation in the proliferative retinopathies.
    Andrew S. Kimmel, Larry E. Magargal, Richard Earl Goldberg · 1989 · PubMed
  43. A systematic review of sodium-glucose cotransporter 2 inhibitors and renal profiles among Japanese patients with type 2 diabetes mellitus
    Junichi Mukai, Nakaba Okamura, Yuki Saito, Rie Kubota · 2023 · Journal of Pharmaceutical Health Care and Sciences
  44. Diabetic nephropathy: Ayur‐nutri‐pharmaco approach
    Kounaina Khan, Subrahmanya Padyana · 2024 · Food Safety and Health
  45. Major adverse kidney events in multidisciplinary chronic kidney disease care compared with usual outpatient care: a propensity score matched analysis
    Palita Chittinandana, Pongsathorn Gojaseni, Anan Chuasuwan, Rattinan Singprasert, Worawon Chailimpamontree, Anutra Chittinandana · 2024 · Journal of Nephrology
  46. 18th Asian Federation of Sports Medicine Congress cum 8th ISN international Sports Medicine & Sports Science Conference
    Asian Federation Of Sports Medicine · 2024 · Sultan Qaboos University medical journal
  47. Audit and Feedback Supporting New Guideline Implementation in Chronic Kidney Disease
    Megan E. Lanpher, Brooke Patterson, Muhammad Ebrahim, Abbas S. Tavakoli · 2025 · Journal of Evaluation in Clinical Practice
  48. Multi-dimensional roles of sodium-glucose cotransporter 2 inhibitors: beyond hypoglycemic and cardiorenal protection
    Siyu Li, Yaqi Wang, Quan Gong · 2025 · Frontiers in Endocrinology
  49. Practice Variation in Prescribing SGLT2-Inhibitors: A Population-Based Analysis from Alberta, Canada
    Rahim Kanji, Derek S. Chew, Flora Au, David J. Campbell, Darren Lau, Reed F. Beall, Paul Everett Ronksley, Braden Manns, Amity E. Quinn · 2025 · CJC Open
  50. Real-world data analysis of the risk of Fournier’s gangrene in patients using sodium-glucose cotransporter 2 inhibitors (SGLT2i)
    Moritz Hertel, Hanno Jaoulak, Max Heiland, Susanne Nahles, Robert Preißner, Saskia Preißner · 2025 · Frontiers in Pharmacology
  51. Sex Differences in Antiarrhythmic Effects of Empagliflozin
    Miyo Nakano, Yusuke Kondo, Shinya Fujiki, Yuki Shiko, Yohei Kawasaki, Yoshihisa Nakagawa, Kazuyoshi Takahashi, Masaaki Okabe, KENGO FUKUSHIMA KUSANO, Shingen Owada et al. · 2026 · JACC Asia
  52. Relationship between glycemic variability and renal function progression in patients with diabetic nephropathy: A retrospective cohort study
    Ling Yang, Bo Zhou, Rensheng Deng · 2026 · Medicine
  53. Anti-obesity medications in adults with congenital heart disease: a comprehensive review and expert clinical recommendations
    Panagiota Mitropoulou, Katja Prokšelj, Andrej Janež, Fernando Riesgo Gil, Suman Verma, Ivana Jurić, Vladimiro Lorenzo Vida, Michael Α. Gatzoulis, Margarita Brida · 2026 · European Heart Journal - Quality of Care and Clinical Outcomes
  54. Combined effect of sodium–glucose cotransporter 2 and dipeptidyl peptidase‐4 inhibitors for diabetic kidney disease
    Shin‐ichi Araki · 2019 · Journal of Diabetes Investigation
  55. Documento de consenso sobre el uso de iSGLT2 en pacientes con enfermedad renal crónica y diabetes
    Ricardo Correa-Rotter, Juan Rosas-Guzmán, Antonio Méndez-Durán, Mario A. Sebastián Díaz, Odette Del C. Díaz-Avendaño, Roopa Mehta-Pravin, Marco A. Alcocer-Gamba · 2022 · Gaceta Médica de México
  56. Influências dos inibidores SGLT2 no sistema cardiovascular de pacientes com Diabetes mellitus tipo 2: uma revisão integrativa
    Ana Laura Caldeira Souza, Artur Rosse Martins, Luciana Martins Lohmann, Karine Siqueira Cabral Rocha · 2022 · Research Society and Development
  57. Pharmacokinetics, Pharmacodynamics and Safety of Janagliflozin in Chinese Type 2 Diabetes Mellitus Patients with Renal Impairment
    Hengli Zhao, Zhirui Zhao, Kun He, Nianrong Mi, Kai Lou, Xiaolin Dong, Wenyu Zhang, Jingfang Sun, Xinyu Hu, Shuguang Pang et al. · 2023 · Clinical Pharmacokinetics
  58. Detection, management, and prevention of diabetes-related foot disease in the Australian context
    Scott E. McNeil, Kate Waller, Yves S Poy Lorenzo, Olimpia C Mateevici, Stacey Telianidis, Sara D. Qi, Irina Churilov, Richard J. MacIsaac, Anna Galligan · 2023 · World Journal of Diabetes
  59. Adverse Events of the Use of SGLT2 Inhibitors in Patients with Heart Failure: A Systematic Review and Meta-analysis
    Mariana Feldner de Britto, Ana Luiza Miranda de Oliveira, Ricardo Simões, Nathália Sernizon Guimarães, Janaíne Cunha Polese, Alessandra Hübner de Souza · 2024 · Journal of Advances in Medicine and Medical Research
  60. New Perspectives on Obesity-Associated Nephropathy from Pathophysiology to Therapeutics: Revealing the Promise of GLP-1 RA Therapy
    Linan Ren, Feng Ju, Siyuan John Liu, Yunjia Cai, Xiaokun Gang, Guixia Wang · 2024 · Drug Design Development and Therapy
  61. Comprehensive Evaluation of the Cardiovascular Protective Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Advanced Chronic Kidney Disease: A Real-World Evidence
    Chih‐Chung Shiao, Ching-Wen Chiu, Yu–Ming Chang, Ming-Che James Liu, Phung-Anh Nguyen, Thanh-Phuc Phan, Chia‐Te Liao, Chih‐Wei Huang, Christianus Heru Setiawan, Hui-Hsin Cheng et al. · 2024 · American Journal of Nephrology
  62. Cardiovascular outcomes and safety assessment of SGLT2i on heart failure patients: a systematic review and meta-analysis
    Radeyah Waseem, Syed Muhammad Moaaz Bin Sultan, Muhammad Sheheryar Hussain, Hussain Haider Shah, Md Ariful Haque · 2025 · Annals of Medicine and Surgery
  63. Diabetes and stroke
    Jennifer Kirsty Burton, Terence J. Quinn, Miles Fisher · 2019 · Practical Diabetes
  64. Possible Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors for Reducing Effects of Blood Glucose and also Blood Pressure
    Hiroshi Bando · 2020 · Asploro Journal of Biomedical and Clinical Case Reports
  65. SGLT2 Inhibitors and the Associated Risk of Genito Mycotic Infections – A Narrative Review
    Sharanya Shre E.S. · 2022 · International Journal of Current Science Research and Review
  66. Precision Medicine Approaches for Management of Type 2 Diabetes
    David Chen, Jordan Fulcher, EMMA S. SCOTT, Alicia Josephine Jenkins · 2022 · Springer eBooks
  67. Új terápiás stratégiák a diabéteszes vesebetegség kezelésében
    Zoltán Balogh · 2022 · Diabetologia Hungarica
  68. Maternal dexamethasone exposure does not affect glucose tolerance but alters renal haemodynamics in F1 rats in a sex‐dependent manner
    Slava A. Malatiali, Narayana Kilarkaje, Maie Al‐Bader · 2023 · Endocrinology Diabetes & Metabolism
  69. Efectividad del uso de inhibidores del cotransportador de sodio-glucosa 2 en la nefropatía diabética
    Karen Julecxi Porras-Reyes, Juan Francisco Novillo-Cevallos · 2023 · MQRInvestigar
  70. Renal protection: What have we learnt from ADVANCE about kidney disease in type 2 diabetes?
    Søren Tang Knudsen, Mark Emmanuel Cooper · 2019 · Diabetes Obesity and Metabolism
  71. Herzinsuffizienzprotektion bei Patienten mit Diabetes mellitus Typ 2 durch SGLT2-Inhibitoren – Evidenzlage und mögliche Mechanismen
    Andreas J. Rieth, Christian W. Hamm, Christoph Wanner, Veselin L. Mitrović, Till Keller · 2020 · Herz
  72. 多層構造ダイヤモンド膜製ナノマニピュレータの研究(マイクロ・ナノ作業1)
    吾朗 関根, 裕一 中里, 肇 宮澤, 貞雄 竹内, 幸則 有賀, 正夫 村川 · 2004 · The Proceedings of JSME annual Conference on Robotics and Mechatronics (Robomec)
  73. О влиянии ингибиторов натрий-глюкозного котранспортера 2 на состояние митохондрий и активность аутофагии
    Алла Алексеевна Колесникова, О. Л. Колесников, Юлия Олеговна Тарабрина · 2021 · Естественные и Технические Науки
  74. Sodium-Glucose Co-transporter-2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Breakthrough in Improvement of Clinical Outcomes?
    Alexander Е. Berezin, Alexander A. Berezin · 2022 · European Medical Journal
  75. Fall, Fracture, and Two Episodes of Euglycemic Diabetic Ketoacidosis
    Waiz Wasey, Sarah Hutchings, Anastasia Dufner, Dorathy Okon, Sharefi Saleh · 2022 · Cureus
  76. Changing the Landscape of Hypertension Management With SGLT2i
    Ines Bilić-Čurčić, Vjera Ninčević, Silvija Canecki-Varžić, Ivana Prpić-Kriẑevac, Jasminka Milas Ahić, Ivica Mihaljević · 2022 · Southeastern European medical journal
  77. Inhibiteurs du cotransporteur sodium-glucose de type 2
    Jamie Falk, Scott W Klarenbach, Cynthia Lam, Jennifer Potter · 2022 · Canadian Family Physician
  78. Sodium-glucose cotransporter-2 inhibitors
    Jamie Falk, Scott W Klarenbach, Cynthia Lam, Jennifer Potter · 2022 · Canadian Family Physician
  79. Reversibility of adverse cardiac remodeling in type 2 diabetes mellitus patients: focus on sodium-glucose cotransporter-2 inhibitors
    Alexander Е. Berezin, Alexander A. Berezin · 2022 · Vessel Plus
  80. Effects of Sodium-Glucose Cotransporter Inhibitor Use in Type 2 Diabetes Mellitus Patients With Heart Failure
    Silpa Choday, N. Ravi, Anusha Parisapogu, Blessing T. Ojinna, M. Sherpa · 2023 · Cureus
  81. USE OF SODIUM-GLUCOSE TRANSPORT PROTEIN 2 (SGLT2) INHIBITORS IN DIABETIC KIDNEY DISEASE (DKD)
    Rio Manuel Rajagukguk · 2023 · Journal of Advance Research in Medical & Health Science
  82. Fibroblast growth factor 23: novel determinants and associations with cardiorenal outcomes
    Maarten de Jong · 2023
  83. ▼Finerenone for CKD associated with type 2 diabetes
    BMJ Publishing Group Ltd · 2023 · Drug and Therapeutics Bulletin
  84. Exploring the Use of Diabetic Medications for Non-Diabetic Conditions: A Comprehensive Literature Review
    Rosemary Iriowen, Temituoyo F. Edema, Victor Dike, Taiwo Ogundipe, I. Oluwatowoju, Bright Chizitere Nwatamole, Ogochukwu A. Okonkwo, Okelue Edwards Okobi · 2023 · American Journal of Health Medicine and Nursing Practice
  85. Comparative Efficacy of Tirzepatide, Teneligliptin, and Empagliflozin in HbA1c Reduction in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
    Jordan Llerena-Velastegui, Fabian Delgado-Quijano, Martin Trujillo-Delgado, Cecibel Villacis‐Lopez, Anthony Fernandez-Arcos, Gerson Santafe-Abril, Claudia Hurtado-Alzate, Karen Benitez-Acosta · 2023 · International Journal of Medical and Surgical Sciences
  86. 2023 UPDATE: Luso-Brazilian evidence-based guideline for the management of antidiabetic therapy in type 2 diabetes
    Marcello Casaccia Bertoluci, Wellington Santana da Silva Júnior, Fernando Valente, Levimar Rocha Araujo, Ruy Lyra, João Jácome de Castro, João Filipe Raposo, Paulo Augusto Carvalho Miranda, César Luiz Boguszewski, Alexandre Hohl et al. · 2023 · Revista Portuguesa de Endocrinologia Diabetes e Metabolismo
  87. Hubungan Efikasi Diri dengan Perawatan Kaki pada Pasien Diabetes Mellitus di Ruang Poli Penyakit Dalam RSD Balung Jember
    Hidayat Hidayat, Luh Titi Handayani, Sofia Rhosma Dewi · 2023 · Health & Medical Sciences
  88. Unveiling renoprotection: A comprehensive review of SGLT2 inhibitors, with emphasis on empagliflozin in the treatment of chronic kidney disease
    Swathi Madagam · 2024 · Urinary and Renal Research
  89. Benefits of using SLGT2 Inhibitors for Patients with CDK and DM2 to Reduce Mortality Risks
    Pandora Eloa Oliveira Fonseca, Jeremias Aguiar Azevedo, Sara Maria Gomes Bié, Sávio Benvindo Ferreira · 2024 · Archives of Pharmacy and Pharmaceutical Sciences
  90. A Bibliometric Analysis of Comorbidity of Heart Failure and Type 2 Diabetes in 2015-2024
    Tianlong Liao, Chengming Wang, Xiaoli Tan, Genyuan Xie, Xiangyang Liu, Fan Ouyang · 2024 · SSRN Electronic Journal
  91. Flozins in Reducing Cardiovascular and Metabolic Risk: A Literature Review
    Daria Sieniawska, Julia Sieniawska, Patrycja Proszowska · 2024 · Quality in Sport
  92. Treatment Outcomes of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Co-Transporter-2 Inhibitors in Diabetes Mellitus with Poor Glycemic Control
    SK Md Humayun Kabir, Md Khairul Islam, Masuma Sultana, Afsana Naznin, Nargis Akter, Md Nur Alam, Adhir Kumar Das · 2024 · Journal of Medicine
  93. Eficácia dos inibidores de SGLT2 no manejo da Doença Renal Crônica com ou sem Diabetes: resultados recentes e perspectivas
    Maria Emília Oliveira de Queiroga, Mateus Werner Gabriel Valença Gomes, Éverton Victor Ferraz de Melo, Leonardo Morais de Andrade, Lucas Felix Silva de Sousa, Blanca Guedes Fragoso Dantas, Mariana Coutinho Marques de Lima, Clara Regina Nascimento Pereira, Luma Vitória Rios do Rêgo, Ilana Laíze Rodrigues Soares et al. · 2024 · Brazilian Journal of Health Review
  94. Cardiac Macrovascular Complications of Diabetes
    Fatma Özpamuk Karadeniz · 2023 · Current Perspective on Diabetes Mellitus in Clinical Sciences
  95. SGLT2 Inhibitors for Primary and Secondary Protection from Cardiovascular and Renal Diseases in Type 2 Diabetes
    Mukesh Nandave · 2024 · Springer eBooks
  96. Concomitant use of sodium-glucose co-transporter 2 inhibitors and metformin and the risk of osteomyelitis reporting: a disproportionality analysis based on FAERS database
    Jiangfan Wu, Xin Wang, Xiaofang Zhao, Shenyin Zhu · 2024 · Expert Opinion on Drug Safety
  97. A validation study of the Intentional Nonadherence Scale among people with type 2 diabetes in the United Kingdom
    Vivien Teo, Anna Hodgkinson, John A Weinman, Mark Chamley, Kai Zhen Yap · 2025 · Diabetic Medicine
  98. HbA1c reduction strategies: An overview of pharmacological interventions
    Krishna S. Upadhye, Hariom Patidar, Narendra Bamnia, Narendra Kumar Yadav · 2025 · National Journal of Pharmacology and Therapeutics
  99. A decade of SGLT2 inhibitors in cardiovascular science: a bibliometric review
    Ahmet Yılmaz · 2025 · Journal of Health Sciences and Medicine
  100. Non-alcoholic fatty liver disease and chronic kidney disease
    Светлана Владимировна Туркина, Тыщенко Ирина Андреевна, М. Н. Титаренко · 2024 · Экспериментальная и клиническая гастроэнтерология